Researchers drew inspiration from easy-to-read weather maps and consulted with doctors to provide guidance at a glance of the likelihood a pathogen will respond to a particular drug in different parts of the state.
“We are building a preclinical drug discovery organization,” says WARF Therapeutics Director Jon Young, who has worked in drug development at Merck Research Laboratories, Regulus Therapeutics and Celgene.
A UW–Madison program aims to give African Americans in Milwaukee strategies to maintain healthy lifestyles that will help prevent and/or manage Type 2 diabetes.
Jason Peters and colleagues have repurposed the gene-editing tool CRISPR to study which genes are targeted by particular antibiotics, providing clues on how to improve existing antibiotics or develop new ones.
A simple blood test could help doctors understand what medication might work best for patients at the start of their treatment, according to new UW–Madison research.
UW–Madison has doctors willing to guide the studies that will make or break cell therapy companies. “If you are a clinician, you need a pioneer spirit to do something that has never been done before,” Jacques Galipeau says, “and there are already many like that here.”
Researchers in pharmacy and bacteriology say their discovery would not have been possible without a cross-college collaboration going back nearly a decade.
To help physicians choose the best antibiotic first, researchers in the School of Pharmacy and the State Cartographer's Office are drawing inspiration from the weather.
A network of researchers in the United States and Canada will try to spare thousands of patients the dangers of heart attacks and hospitalizations over the next five years in a trial of a high-dose flu vaccine.